Neathera is a clinical-stage biotechnology company focused on autoimmune and complement-mediated diseases, dedicated to translating advanced immunology into scalable and commercially viable antibody therapeutics. The company is driven by clearly defined clinical unmet needs and targets disease areas with high burden, limited treatment options, and stringent requirements for safety, dosing convenience, and patient usability.
Neathera has established an AI-enabled, integrated antibody engineering and CMC translational platform that seamlessly connects molecular design, engineering optimization, developability assessment, process development, and clinical translation. Supported by standardized and modularized process and formulation capabilities, the platform enables rapid progression from candidate selection to clinical-ready injectable products within 12–14 months, with a strong focus on long-acting, high-concentration subcutaneous biologics.
Neathera’s lead program, EA5, is a long-acting C5 complement inhibitor currently in clinical development for multiple complement-driven diseases, with potential expansion into first-in-class indications. In parallel, the company continues to advance a pipeline of innovative antibody candidates generated through its platform, establishing a repeatable, clinically driven engine for producing high-quality, development-ready assets. Neathera’s long-term vision is to become a differentiated leader in autoimmune drug development through engineering excellence and translational execution.
